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Abstract
Myotonic dystrophy type 2 (DM2) is a progressive muscular dystrophy with multi-system manifestations and can affect functional mobility, gait,
and balance. Currently, there are few reports of functional outcome measures in this population. This case describes the change in function detected
by the High-level Mobility Assessment Tool (HiMAT) and 30-second Chair Stand Test (CST) in a high-functioning adult female with DM2 after
physical therapy treatment. The patient’s chief complaint was muscular pain and fatigue that affected activities of daily living (ADLs). Multimodal physical therapy focused on neuromuscular re-education, balance and strength training, patient education, and moderate cardiorespiratory
training. Improvements were observed in manual muscle testing and in single-limb standing balance. A nine-point total improvement was observed
in HiMAT score, and the CST detected a 100% improvement in number of sit-to-stands. The patient returned to prior level of function and was able
to resume ADLs and recreational activities without complaints of muscular pain or fatigue.

Keywords: Physical function in DM2; HiMAT; Physical therapy; Neuromuscular rehabilitation; Chair stand test; Functional outcome measures
Abbreviations: ADLs – activities of daily living; CCTG – tetranucleotide (cytosine-cytosine-thymine-guanine) expansion; DM1 – myotonic

dystrophy type 1; DM2 – myotonic dystrophy type 2; J.D. – patient pseudonym (Jane Doe); LE – lower extremity; LLE – left lower extremity; LOB
– loss of balance; MMT – manual muscle testing; PROMM – proximal myotonic myopathy; PT – physical therapy / physical therapist; RLE – right

Introduction
Myotonic Dystrophy type 2 (DM2), or Proximal Myotonic
Myopathy (PROMM), is a late-onset inherited and progressive muscular
dystrophy with multi-system manifestations [1-5]. The etiology of DM2
is traced to a tetranucleotide (CCTG) repeat expansion located on the
CNBP gene resulting in abnormal cardiac and skeletal muscle function
[6-9]. Despite having similar features to Myotonic Dystrophy type 1
(DM1), DM2 is clinically distinct, originating from a different gene
locus [1,2,4,10]. DM2 is characterized by a milder clinical presentation,
later onset of symptoms, and more proximal versus distal weakness
[4,5,9,11]. Other clinical features include somnolence, weakness, muscle
pain and stiffness, cramping and fatigue, which impact quality of life
[1,6,8]. Compared to DM1, DM2 is less severe and the exact prevalence
is a topic of ongoing study [7-9,12].
Similar to DM1, a hallmark feature of DM2 is myotonia [6-8]. Grip
myotonia is often the first symptom experienced with noticeable delay
in the relaxation of the long finger flexors [6,8]. Myotonia may also be
noted in the calf musculature or in the thumb. DM2 selectively affects
the neck flexors, long finger flexors, elbow extensors, and proximal
girdle musculature [1,6,8]. Hip flexor and extensor weakness can
disrupt functional mobility, particularly during ambulation and stair
climbing [3,5-8,11]. Persons with DM2 may vary in the degree to which
the disease impacts functional mobility [6]. Therefore, any number of
physical performance or functional outcome measures may be selected
to monitor change or response to treatment. However, there are few
published studies that have utilized functional outcome measures in the
assessment of persons with DM2.
*Corresponding author: Kim B. Smith, PT, DPT, Assistant Professor of
Physical Therapy, Nova Southeastern University, Department of Physical
Therapy, 3200 South University Dr., Fort Lauderdale, FL 33328, USA. Tel:
954-262-1746; E-mail: ksmith@nova.edu
Received: Aug 02, 2018; Accepted: Aug 13, 2018; Published: Aug 16,
2017

The High-level Mobility Assessment Tool (HiMAT) appears to
be an appropriate measure of functional mobility for persons with
DM2. The HiMAT has previously demonstrated sound psychometric
properties and has been normative referenced in healthy subjects [1319]. These properties have led to the application of the HiMAT as a
valid and reliable measurement tool in the outpatient rehabilitation
of persons with other neurological disorders. Furthermore, repetitive
sit-to-stand testing is frequently used as an indicator of functional
strength in the lower extremities and has been widely studied across
populations [20-23]. However, to date, there have been no published
reports examining the use of either the HiMAT or the 30-sec Chair
Stand Test (CST) in persons with DM2. Therefore, the purpose of this
case report is to describe the use of the HiMAT and CST in a patient
with DM2 undergoing an outpatient multi-modal Physical Therapy
(PT) treatment.

Case Report
Patient Background
An ambulatory 46-year-old Caucasian female, referred to as Jane
Doe (J.D.) and diagnosed with DM2 by a neurologist at age 33 years,
presented to an outpatient PT clinic with no apparent functional
limitations. J.D. reported independence with all functional Activities of
Daily Living (ADLs). J.D is a stay-at-home mother of three school-aged
children. A typical daily schedule consists of moderate physical activity
demands during meal preparation, basic and heavy-duty housekeeping
(cleaning/laundry), driving, shopping and running errands. The chief
complaint was muscle pain and weakness during prolonged activity,
especially squatting and walking, with an overall goal to restore
strength and return to running and gym-based exercises. J.D. reported
experiencing pain (5/10 at worst) in her legs and difficulty with sit-tostand activities. J.D. had been unable to participate in normal exercise
for the prior six months due to disease-related symptoms. Written
informed consent was obtained prior to treatment, as well as for
inclusion in this case report.
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Examination
Upon PT examination, a standing postural assessment revealed
lumbar hyperlordosis and knee hyperextension. A slight resting tremor
was noted bilaterally in the upper and lower extremities. No deficits
in active or passive range of motion were found in the upper or lower
extremities. Isometric break testing revealed grossly normal strength
for bilateral upper extremities. Manual Muscle Testing (MMT) was
performed more extensively in the lower extremities and results can be
found in Table 1. MMT was performed according to procedures and
positions outlined by Kendall FP et al. [24] Proximal muscle weakness
was noted in the hip and knee joints with the left side being slightly
more affected. Ankle dorsiflexion strength was found to be within
normal limits. Ankle plantarflexion strength was tested using the
multiple heel-rise in standing with no deficits. However, a prolonged
lowering time after heel-rise was observed indicating a delayed muscle
relaxation consistent with myotonia. Observational gait analysis
revealed independent ambulation and a normal reciprocal pattern
without noticeable deviations. J.D. could successfully ascend and
descend a flight of stairs using a reciprocal pattern without the use of
upper extremity support but was slower and appeared cautious.

Outcome Measures
The HiMAT was
selected to assess the response to more challenging mobility demands
in this case. The HiMAT was originally developed to assess balance in
high-functioning survivors of traumatic brain injury to quantify the
need for assistance with functional mobility [13-19]. The tool requires
that participants be able to ambulate at least 20-meters without assistive
devices or orthoses [13]. The HiMAT contains multiple test items,
including: walking, running, skipping, hopping, bounding, jumping,
and stair negotiation [13-15]. Participants complete each item at
the safest maximum speed possible [13-15]. The test is hierarchical
in nature and consists of thirteen total items based upon a five-point
scale, where higher scores equate to increasing performance, as seen
in Table 2. Normative values of the HiMAT have been established for
healthy young adults (ages 18-25 years) with high test-retest reliability
(ICC=0.88, 95% CI 0.82-0.92) [13,18]. The HiMAT has demonstrated
great psychometric properties including external concurrent validity,
excellent reliability [0.88-0.99], high internal consistency [0.91-0.95],
and low standard error of measurement (SEM)[0.79-1.36] [16-19].
High-level Mobility Assessment Tool (HiMAT):

Chair Stand Test (CST)
Functional strength of the lower extremities was assessed using
the CST [20]. This test was selected as it requires repetitive movement
using proximal musculature over 30 seconds. This test allows for the
observation of the effects of proximal weakness or the prolonged muscle
relaxation characteristic of DM2 on functional mobility. Strong testTable 1: Results of Manual Muscle Testing.
Muscle / Muscle Group (test position)

Initial Evaluation

J Phy Med Rehab. 2018; 1:109 | Page 2 of 5

retest reliability and validity of the CST have been found in healthy
community-dwelling adults, among other populations [20-25]. This test
was performed in accordance with prior studies [20-25].

Standing Balance Assessment
Clinical balance assessment was performed using the single- and
double-limb standing balance test with eyes-opened or eyes-closed on
a firm surface. This test was performed in accordance with prior studies
and occurred over 30 seconds in each position [26].

Treatment
J.D. received PT treatment once a week for eight consecutive weeks.
The goals of PT intervention were to:

1.)

Return to prior levels of daily function and physical activity without
onset of fatigue, pain, or weakness;

2.)

Return to a gym-based fitness program and recreational running;
and

3.)

Restore quality of life.

PT interventions included light to moderate resistance training
of the pelvic and shoulder girdle muscles and neuromuscular reeducation techniques concentrating on improving motor and postural
control to prevent movement compensations. Postural stabilization
techniques in developmental positions such as high kneeling and
quadruped were utilized. Tactile and verbal cueing was utilized to
correct movement dysfunction during treatment sessions. Single limb
stance balance training, reciprocal movement coordination training,
and cardiorespiratory conditioning were also employed. For this case,
submaximal cardiorespiratory training was performed at a lightmoderate intensity (40-60% of HRR) and slowly progressed as tolerated
[27] The Borg rate of perceived exertion (RPE) (6-20) was used to
monitor patient effort during all activities. Patient education stressed
complete muscle relaxation between repetitions and limited repetitions
based upon movement quality. A key component of the treatment plan
included tracking the response to treatment to allow for the optimal
modification and progression of exercise dose and intensity. Therefore,
J.D. kept a daily log of activities and recorded muscle pain, weakness,
fatigue and functional decline. Each treatment session began with an
activity log review and served as the basis to progress or modify the PT
treatment plan. A summary of the patient activity log (response to prior
treatment), clinical reasoning, and intervention for each PT visit can be
found in Supplemental Table 1.

Results
At the completion of eight weeks in PT, strength, single-limb
standing balance, and functional performance improved. Results of
MMT can be found in Table 1. Hip and knee strength improved on
Week 4 Re-evaluation

Right

Left

Right

Hip Flexors (seated)

4+/5

4+/5

4+/5

Hip Abductors (side lying)

4+/5

4/5

Hip Adductors (side lying)
Gluteus Maximus
(prone-knee flexed to 90deg.)
Biceps Femoris
(prone-knee extended)
Knee Flexors (prone)

4+/5

Knee Extensors (seated)

Week 8 Re-evaluation prior to d/c

Left
4+/5

Right

Left

4+/5

4/5

4+/5

4/5

5/5

4+/5

4/5

4+/5

4/5

5/5

5/5

3+/4

3/5

4/5

4/5

4+/5

4/5

3+/5

4/5

4+/5

4+/5

5/5

4+/5

3+/5

3/5

5/5

4+/5

5/5

4+/5

3+/5

3/5

4+/5

4+/5

5/5

5/5

*Manual muscle testing (MMT) grading scale according to Kendall & McCreary, Muscles: Testing and Function (1983)
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Table 2: HiMAT results at initial examination, re-evaluation, and discharge.
HiMAT item
Category

Initial Evaluation
Performance

Week 4 Re-evaluation

Week 8 Re-evaluation

Score

Performance

Performance

Score

Score

10-m Walk

4.62 s

3

4.13 s

4

4.67 s

3

10-m Walk Backward

10.27 s

2

5.51 s

4

6.02 s

3

10-m Walk on Toes

6.64 s

3

5.13 s

4

6.00 s

3

10-m Walk over Obstacles

6.15 s

2

4.61 s

3

3.92 s

4

10-meter Run

2.32 s

2

1.85 s

3

1.58 s

4

10-m Skip

3.32 s

3

3.01 s

3

3.29 s

3

10-m Hop Forward

5.40 s

2

5.13 s

3

6.31 s

2

Bound- Affected LE

93.1cm

2

100.43cm

2

121.6cm

3

Bound – Less-Affected LE

105.3cm

2

110cm

3

124.7cm

3

Up Stairs- Dependent

Reciprocal no rail

5

Reciprocal no rail

5

Reciprocal no rail

5

Up Stairs-Independent

7.66 s

2

6.82 s

3

5.22 s

4

Down Stairs-Dependent

Reciprocal no rail

5

Reciprocal no rail

5

Reciprocal no rail

5

Down Stairs- Independent

5.54 s

4

4.43 s

4

3.08 s

4

Total Score ___/54

37

46

46

High-Level Mobility Assessment Tool1-3, cm – centimeter, m – meter, LE – Lower extremity, s – seconds
MMT. J.D. returned to exercising 4-5 times/week alternating between
the gym, running, and a home exercise program. Single-limb balance
eyes-open on a firm surface improved from 25 sec (LLE) and 30 sec
(RLE) to 60 sec bilaterally; single limb balance eyes-closed on a firm
surface improved from inability to perform (0.0 sec) (bilaterally) to
17.29 sec on RLE and to 5.65 sec on LLE.
Results for the HiMAT can be found in Table 2. On initial
examination J.D. scored 38/54 and fell below the normative value range
of 44-54 for a healthy adult female aged 18-25 [13,15-17,19]. At week
5, her score on the HiMAT improved by 15% to a 46/54. The HiMAT
score was stable between week five and the final visit. Initially, J.D.
completed 10 stands in the allotted 30-seconds of the CST and scored
15%ile, equivalent for a woman aged 60-64 years [20]. Upon completion
of the test she reported a score of 18 “very hard” Borg RPE (6-20) [29].
The CST improved by 50% to 15 stands on reassessment at week five
and to 20 stands prior to discharge at week ten, yielding a 100% total
improvement. This resulted in a total change from 15%ile on initial
evaluation to 75%ile prior to discharge on comparative normative data.

Discussion
Overall, there is a dearth of published outcome measures for persons
with DM2. This case highlights the utility of the HiMAT and the CST
as novel and appropriate measures for further investigation in the DM
population. This case provides an example of how PT intervention
assisted a person with DM2 and demonstrates improvements in balance
and function. The results of this case report support the value of PT
in helping persons with DM2 learn about managing their condition to
optimize functional mobility and activity participation.
In this case, the HiMAT detected an overall improvement in function
that persisted across weeks of repeated measurement. J.D.’s ability to
perform repetitive sit-to-stand was reflected in the 100% change from
the baseline score. The increase in the HiMAT score on reassessment
was further supported by her return to prior level of function and
gym-based exercise and running. The increase in some HiMAT score
categories and decrease in others could possibly be explained by a
cumulative effect of muscles fatigue on performance through the test
item progression, or by a potential training effect. Further inquiry on
the HiMAT and CST is warranted across neuromuscular populations to
establish reliability and validity of the tool. Future research and clinical

trials should consider utilizing the HiMAT and CST as a measure of
physical function to monitor change in response to intervention.
Critical to this case was continually evaluating the patient’s
response to treatment using an activity log. Managing the immediate
effects of DM2 during PT treatment included allowing extra time for
muscle relaxation between exercise repetitions and limiting exercise
to a muscle group indicated by cramping and/or onset of tremor.
Patient education was essential to the patient’s progress to address
complete muscle relaxation between repetitions to reduce myotonia.
The integration of developmental postures in the PT treatment plan was
instrumental in promoting motor learning of the proximal and core
stabilization muscles in the absence of movement substitutions patterns
or compensations.
DM2 is a rare neuromuscular disorder. Persons with DM2
may benefit from physical therapy treatment to address functional
impairments such as muscle weakness, pain, stiffness, decreased
endurance, and activity limitations that are commonly associated
with the disorder. Furthermore, other clinical features of DM2
include conductive cardiac disease and progressive cardiomyopathy
[2,5,7,11,30,31]. The frequency and severity of cardiac involvement in
DM2 is less than in DM1 [32]. However, the risk for cardiac arrhythmia
and other complications do exist [32]. Physical therapists should be
aware of the potential for asymptomatic cardiomyopathy, heart failure,
and risk for serious cardiac complications when treating persons with
DM2. Therefore, physician clearance prior to initiating an exercise
program is imperative and should always be obtained. However, the
parameters of an optimal cardiorespiratory exercise program are not
yet fully understood for persons with DM2 and should be a topic of
future study.
There are limitations to this case report, including a single-subject
report. The lack of an objective quantitative measure of muscle strength
(i.e., handheld dynamometry) was also a limitation in this case report.
Therefore, the results and interpretation of the responsiveness of the
HiMAT in this case is cautioned as a possible training effect could
have impacted the change in performance. Additionally, various
mechanisms have been found to generate musculoskeletal pain in DM2
including exercise, temperature, and palpation [32]. Routine physical
activity may help to control musculoskeletal pain, and this appears to be
supported in this case [33]. Rehabilitation providers should understand
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the potential for symptom exacerbation with resistive exercise in
persons with neuromuscular disorders. However, currently, it is not yet
fully known how prescribing resistive exercise can affect the degree to
which skeletal or cardiac muscle function may be enhanced or further
impaired in DM2. Similarly, it is not yet fully understood how various
levels of exercise training may enhance or impair myotonia [30].
Therefore, therapists should use caution when implementing a strength
or cardiorespiratory training program in persons with DM2.
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Implications for Rehabilitation
•

The High-level Mobility Assessment Tool can detect change in
function in DM2.

•

The 30-second Chair Stand Test can detect improvements in muscle
strength in DM2.

•

Improvements in manual muscle testing were noted after physical
therapy treatment.

•

Exercise and physical therapy can promote return to function in a
person with DM2.
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